- Stocks
- Healthcare
- NASDAQ: EDIT

Price (delayed)

$38.16

Market cap

$2.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.59

Enterprise value

$2.3B

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a

Editas Medicine's gross profit has soared by 149% YoY but it has decreased by 11% from the previous quarter

The revenue has soared by 149% year-on-year but it has declined by 11% since the previous quarter

Editas Medicine's net income has decreased by 26% YoY and by 23% QoQ

EDIT's EPS is down by 17% since the previous quarter and by 3.2% year-on-year

What are the main financial stats of EDIT

Market
Valuations
Earnings

Shares outstanding

68.26M

Market cap

$2.6B

Enterprise value

$2.3B

Price to earnings (P/E)

N/A

Price to book (P/B)

4.22

Price to sales (P/S)

31.92

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

28.31

Revenue

$81.14M

EBIT

-$167.4M

EBITDA

-$162.76M

Free cash flow

-$189.3M

Per share
Balance sheet
Liquidity

EPS

-$2.59

Free cash flow per share

-$2.79

Book value per share

$9.04

Revenue per share

$1.2

TBVPS

$11.14

Total assets

$755.88M

Total liabilities

$142.52M

Debt

$30.26M

Equity

$613.36M

Working capital

$550.28M

Debt to equity

0.05

Current ratio

9.34

Quick ratio

9.25

Net debt/EBITDA

1.89

Margins
Efficiency
Dividend

EBITDA margin

-200.6%

Gross margin

100%

Net margin

-205.4%

Operating margin

-208.5%

Return on assets

-24.6%

Return on equity

-32%

Return on invested capital

-45.8%

Return on capital employed

-24.3%

Return on sales

-206.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Editas Medicine stock price performed over time

Intraday

0.9%

1 week

-0.31%

1 month

-35%

1 year

16.48%

YTD

-45.57%

QTD

-7.11%

How have Editas Medicine's revenue and profit performed over time

Revenue

$81.14M

Gross profit

$81.14M

Operating income

-$169.17M

Net income

-$166.66M

Gross margin

100%

Net margin

-205.4%

Editas Medicine's gross profit has soared by 149% YoY but it has decreased by 11% from the previous quarter

The revenue has soared by 149% year-on-year but it has declined by 11% since the previous quarter

EDIT's operating margin has surged by 55% year-on-year but it is down by 31% since the previous quarter

The net margin has grown by 49% YoY but it has contracted by 39% from the previous quarter

What is Editas Medicine's growth rate over time

What is Editas Medicine stock price valuation

P/E

N/A

P/B

4.22

P/S

31.92

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

28.31

EDIT's EPS is down by 17% since the previous quarter and by 3.2% year-on-year

EDIT's equity is up by 44% year-on-year but it is down by 3.9% since the previous quarter

EDIT's P/B is 35% below its last 4 quarters average of 6.4 and 25% below its 5-year quarterly average of 5.6

The revenue has soared by 149% year-on-year but it has declined by 11% since the previous quarter

The P/S is 52% less than the 5-year quarterly average of 66.1 and 11% less than the last 4 quarters average of 35.5

How efficient is Editas Medicine business performance

EDIT's return on sales has surged by 51% year-on-year but it is down by 39% since the previous quarter

EDIT's return on invested capital is up by 35% year-on-year

The ROE has increased by 31% YoY but it has decreased by 13% from the previous quarter

Editas Medicine's ROA has decreased by 19% from the previous quarter but it has increased by 7% YoY

What is EDIT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EDIT.

How did Editas Medicine financials performed over time

EDIT's total liabilities is down by 38% year-on-year

EDIT's total assets is up by 15% YoY but it is down by 3.1% QoQ

The debt is 95% less than the equity

EDIT's equity is up by 44% year-on-year but it is down by 3.9% since the previous quarter

The company's debt to equity fell by 29% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.